{
    "clinical_study": {
        "@rank": "67347", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain\n      protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV\n      drugs. This study also examines how the body processes these drugs when they are given\n      together."
        }, 
        "brief_title": "A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this Phase II, open-label study patients (16 per treatment group) are randomized to\n      receive 1592U89 in combination with one of five protease inhibitors: indinavir, saquinavir,\n      ritonavir, nelfinavir, or 141W94 for up to 48 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Local treatment for Kaposi's sarcoma.\n\n          -  GM-CSF, G-CSF or erythropoietin.\n\n        Patients must have:\n\n          -  HIV-1 infection documented by a licensed HIV-1 antibody ELISA and confirmed by\n             Western blot detection of HIV-1 antibody or a positive HIV-1 blood culture.\n\n          -  CD4+ cell count >= 100 cells/mm3 within 14 days of study drug administration.\n\n          -  HIV-1 RNA >= 5,000 copies/ml within 14 days of study drug administration.\n\n          -  No active or ongoing AIDS-defining opportunistic infection or disease.\n\n          -  Signed, informed consent from parent or legal guardian for patients less than 18\n             years of age.\n\n        Prior Medication:\n\n        Allowed:\n\n        Local treatment for Kaposi's sarcoma.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Malabsorption syndrome, or other gastrointestinal dysfunction, that might interfere\n             with drug absorption or render the patient unable to take oral medication.\n\n          -  Life-threatening infection or other serious medical condition that may compromise a\n             patient's safety.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other investigational agents. NOTE:\n\n          -  Those available through Treatment IND or expanded access programs are evaluated\n             individually.\n\n          -  Chemotherapeutic agents for the initial 24 weeks of study (except local treatment for\n             Kaposi's sarcoma).\n\n          -  Agents with documented anti-HIV activity in vitro.\n\n          -  Foscarnet.\n\n          -  Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide,\n             anti-cytokine agents or interferons.\n\n          -  Antioxidants.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        Radiation therapy within the first 24 weeks of study.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of clinically relevant pancreatitis or hepatitis within the last 6 months.\n\n          -  Participation in an investigational HIV-1 vaccine trial.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Antiretroviral therapy, including reverse transcriptase inhibitor and protease\n             inhibitor therapy.\n\n          -  Cytotoxic chemotherapeutic agents within 30 days of study drug administration.\n\n          -  HIV-1 vaccine dose within the 3 months prior to study drug administration.\n\n          -  Immunomodulating agents, such as systemic corticosteroids, interleukins or\n             interferons within 30 days of study drug administration.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Radiation therapy within 30 days of study drug administration. Alcohol or illicit drug use\n        that may interfere with patient compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": "80", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002440", 
            "org_study_id": "238J", 
            "secondary_id": "CNAA2004"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Saquinavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Indinavir", 
                "Saquinavir", 
                "Ritonavir", 
                "Nelfinavir", 
                "Amprenavir", 
                "HIV Protease Inhibitors", 
                "Anti-HIV Agents", 
                "Abacavir", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "HIV-1", 
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Mutation", 
            "HIV-1 Reverse Transcriptase", 
            "HIV Protease", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "921036329"
                    }, 
                    "name": "UCSD Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "065102483"
                    }, 
                    "name": "Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Kansas City AIDS Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Med Ctr / Dept of Medicine / AIDS Clinical Trial"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28232"
                    }, 
                    "name": "Carolinas Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western Reserve Univ / AIDS Clinical Trials Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Univ of Pittsburgh Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "372321302"
                    }, 
                    "name": "Vanderbilt Univ Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label, Phase II Trial to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of 1592U89 in Combination With Selected HIV-1 Protease Inhibitors in Antiretroviral-Naive, HIV-1-Infected Patients.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002440"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Carolinas Med Ctr": "35.227 -80.843", 
        "Case Western Reserve Univ / AIDS Clinical Trials Unit": "41.499 -81.695", 
        "Kansas City AIDS Research Consortium": "39.1 -94.579", 
        "NYU Med Ctr / Dept of Medicine / AIDS Clinical Trial": "40.714 -74.006", 
        "UCSD Treatment Ctr": "32.715 -117.157", 
        "Univ of Pittsburgh Med Ctr": "40.441 -79.996", 
        "Vanderbilt Univ Med Ctr": "36.166 -86.784", 
        "Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit": "41.308 -72.928"
    }
}